Corvus Pharmaceuticals, Inc.CRVSNASDAQ
LOADING
|||
Cash Flow Under Pressure
Above historical average, modest growth trend.
Left:
||||
Operating cash flow minus capital expenditures
Latest
$-25.42M
↑ 20% above average
Average (9y)
$-31.66M
Historical baseline
Range
High:$-13.07M
Low:$-46.48M
CAGR
+7.7%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $-25.42M | -6.1% |
| 2023 | $-23.97M | +12.2% |
| 2022 | $-27.29M | +25.7% |
| 2021 | $-36.72M | -5.4% |
| 2020 | $-34.85M | +6.7% |
| 2019 | $-37.35M | +9.7% |
| 2018 | $-41.34M | +11.0% |
| 2017 | $-46.48M | -54.6% |
| 2016 | $-30.06M | -129.9% |
| 2015 | $-13.07M | - |